2015
Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica 2015, 100: 794-800. PMID: 25795722, PMCID: PMC4450625, DOI: 10.3324/haematol.2015.123711.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaComplete remissionRecombinant immunotoxinCommon adverse eventsDose-escalation trialLow tumor burdenAssessment Tool scoreDurable remissionsEscalation trialPartial remissionAdverse eventsTumor burdenIntravenous infusionPatientsRemissionTool scoreResponse rateSingle-chain antibody fragmentChain antibody fragmentsLymphomaDiphtheria toxinFurther studiesImmunotoxinTrials
2003
Peripheral T- cell lymphomas: diagnosis and management
Dearden CE, Foss FM. Peripheral T- cell lymphomas: diagnosis and management. Hematology/Oncology Clinics Of North America 2003, 17: 1351-1366. PMID: 14710889, DOI: 10.1016/s0889-8588(03)00119-9.Peer-Reviewed Original ResearchConceptsFirst-line therapyT-cell lymphomaCampath-1HResponse rateLine therapyPurine analoguesT-PLLAllogeneic bone marrow transplantationPeripheral T-cell lymphomaThird of patientsFavorable prognostic factorBone marrow transplantationMonoclonal antibody therapyStem cell transplantationNon-randomized studiesMature T-cell neoplasmsMinimal residual diseaseT-cell neoplasmsHigh response rateT-cell malignanciesLargest disease groupRisk of toxicityDurable remissionsRefractory patientsPreparative regimens